New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
06:04 EDTAZN, DTVStocks with implied volatility below IV index mean; AZN DTV
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 26, DirecTV (DTV) 13.
News For AZN;DTV From The Last 14 Days
Check below for free stories on AZN;DTV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
08:00 EDTAZNFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
September 15, 2014
18:36 EDTDTVEntropic, ViXS Systems settle all litigation, execute cross-license pact
Entropic (ENTR) and ViXS Systems announced they have settled all outstanding litigation between the companies and have agreed to a cross-license to the patents at issue in the litigation. Entropic, ViXS and certain of their subsidiaries have been engaged in several patent lawsuits in the federal courts as well as proceedings before the International Trade Commission. Under the settlement agreement, all outstanding claims and counterclaims in those actions will be dismissed against all defendants, including DIRECTV (DTV), Wistron NeWeb Corporation and CyberTAN. The settlement also includes a cross-license between Entropic and ViXS of the issued patents that were the subject of the litigation. No fees or royalties are payable by either party with respect to its business as currently conducted or planned. Other terms of the settlement were not disclosed. The companies each expressed satisfaction with the litigation settlement.
07:27 EDTAZNPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 12, 2014
10:32 EDTAZNPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
09:31 EDTDTVDirecTV aiming for AT&T deal to close late 1Q15, early 2Q15
In regards to DirectTV's (DTV) merger with AT&T (T), the company says its next big milestone is the completion of the formal shareholder vote. Says confident in having "overwhelming support" from shareholders. Says in terms of the merger's regulatory process, its going how the company expected. Says optimistic about closing the deal during 1H15. Ideally, says would like to see the deal close in late Q1 or early Q2, specifically "early April." Says highly confident in completing "Sunday Ticket" deal with the NFL before the end of the year. Says digital economy becoming increasingly important to consumers. Says merger with AT&T "unlocks" opportunities in Latin America. Says content costs could run "too high" for some customers. Says company needs to find a $25-$50 TV package for low spenders. Says looking for niche entertainment content. Aims to have capabilities for streaming next year. Comments made during the company's presentation at the Goldman Sachs Communacopia Conference.
06:29 EDTDTVUnivision supplys content for DirecTV service by FY14 end, Reuters says
Subscribe for More Information
September 11, 2014
13:06 EDTDTVDeal probe expanded to AT&T, DirecTV agreement, Reuters says
The state attorneys general who are collaborating with the U.S. Justice Department to figure out if Comcast's (CMCSA) purchase of Time Warner Cable (TWC) is permissible have broadened their probe to also incorporate AT&T's (T) potential acquisition of DirecTV (DTV), according to Reuters, citing sources close to the merger investigation. Reference Link
September 10, 2014
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
10:00 EDTDTVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:31 EDTDTVGoldman to hold a conference
Subscribe for More Information
06:04 EDTDTVDirecTV initiated with a Hold at Canaccord
Subscribe for More Information
September 8, 2014
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexium’s brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
September 5, 2014
05:19 EDTDTVDirecTV calls on Raycom Media to free NFL, college football games
Subscribe for More Information
September 4, 2014
17:15 EDTAZNAstraZeneca granted orphan status for EFGR non-small cell lung cancer treatment
The FDA posted on its website that AstraZeneca has been granted orphan status for its treatment of epidermal growth factor receptor, or EFGR, mutation-positive non-small cell lung cancer. Reference Link
07:23 EDTAZNAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
September 3, 2014
05:44 EDTAZNTeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use